A detailed history of Mariner, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Mariner, LLC holds 16,782 shares of NBIX stock, worth $2.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,782
Previous 19,889 15.62%
Holding current value
$2.12 Million
Previous $2.74 Million 29.44%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$114.58 - $153.15 $356,000 - $475,837
-3,107 Reduced 15.62%
16,782 $1.93 Million
Q2 2024

Aug 13, 2024

BUY
$130.86 - $143.19 $51,689 - $56,560
395 Added 2.03%
19,889 $2.74 Million
Q1 2024

May 15, 2024

BUY
$130.4 - $143.74 $312,568 - $344,544
2,397 Added 14.02%
19,494 $2.69 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $649,042 - $812,358
6,119 Added 55.74%
17,097 $2.25 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $62,993 - $78,457
670 Added 6.5%
10,978 $1.24 Million
Q2 2023

Aug 11, 2023

BUY
$89.53 - $104.87 $35,364 - $41,423
395 Added 3.98%
10,308 $972,000
Q1 2023

May 12, 2023

SELL
$94.11 - $123.02 $64,371 - $84,145
-684 Reduced 6.45%
9,913 $1 Million
Q4 2022

Feb 14, 2023

SELL
$106.72 - $127.06 $126,249 - $150,311
-1,183 Reduced 10.04%
10,597 $1.27 Million
Q3 2022

Nov 10, 2022

BUY
$92.03 - $107.81 $11,871 - $13,907
129 Added 1.11%
11,780 $1.25 Million
Q2 2022

Aug 15, 2022

BUY
$75.79 - $100.07 $64,800 - $85,559
855 Added 7.92%
11,651 $1.14 Million
Q1 2022

May 13, 2022

BUY
$72.45 - $94.81 $782,170 - $1.02 Million
10,796 New
10,796 $1.01 Million
Q3 2019

Nov 13, 2019

SELL
$83.82 - $101.5 $221,033 - $267,655
-2,637 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $1,228 - $1,551
-17 Reduced 0.64%
2,637 $223,000
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $183,948 - $242,920
2,654 New
2,654 $234,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.